ARTICLE | Clinical News
Gaboxadol: Ph II STARS started
February 10, 2017 9:19 PM UTC
Ovid began the double-blind, placebo-controlled, U.S. Phase II STARS trial to evaluate once- and twice-daily oral gaboxadol in about 75 patients. Ovid has exclusive, worldwide rights to gaboxadol from...
BCIQ Target Profiles